📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. (2018)

First Author: Mori G

Attributed to: More Medicines for Tuberculosis funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.tube.2018.08.004

PubMed Identifier: 30205975

Publication URI: http://europepmc.org/abstract/MED/30205975

Type: Journal Article/Review

Volume: 112

Parent Publication: Tuberculosis (Edinburgh, Scotland)

ISSN: 1472-9792